Document is current
Any future updates will be listed below
-
Authors
Pencina, Karol M.
Thanassoulis, George
Pencina, Michael J.
Toth, Peter P.
Sniderman, Allan D.
-
Funding
Funding for this research was provided by:
Mike and Valeria Rosenbloom Foundation
- License Information
-
More Information
Article History
Received: 19 August 2024
Accepted: 25 November 2024
First Online: 19 December 2024
Declarations
:
: Dr. Karol Pencina reports funding from the non-profit Doggone Foundation. Dr. George Thanassoulis has participated in advisory boards or speaker bureaus for Amgen, Regeneron/Sanofi, HLS therapeutics, Ionis, Servier, Novartis, Silence and has received grant funding from Servier and Ionis. Dr. Michael Pencina reports funding from the non-profit Doggone Foundation, consulting fees from Cleerly Inc and advisory board fees from Eli Lilly and Janssen. Dr. Peter Toth is a member of the speaker’s bureau for Amgen, Lilly, and Novo-Nordisk; he is a consultant to Lilly, Merck, and Novartis. Dr. Allan Sniderman has no conflict of interest.
